Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma

NCT01366157 | Completed

• 4 other identifiers: AHOD11B1COG-AHOD11B1CDR0000701020NCI-2011-02859
• Study Type: observational
• Target: 23
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research trial is studying protein biomarker levels in tissue samples from young patients with low-risk Hodgkin lymphoma.

Conditions

Lymphoma

Keywords

childhood favorable prognosis Hodgkin lymphoma; stage I childhood Hodgkin lymphoma; stage II childhood Hodgkin lymphoma; stage III childhood Hodgkin lymphoma; stage IV childhood Hodgkin lymphoma; childhood lymphocyte depletion Hodgkin lymphoma; childhood lymphocyte predominant Hodgkin lymphoma; childhood mixed cellularity Hodgkin lymphoma; childhood nodular lymphocyte predominant Hodgkin lymphoma; childhood nodular sclerosis Hodgkin lymphoma

Outcome Measures

Primary Outcomes (4)

• Variability of HGAL protein expression in pediatric patients with low-risk classical Hodgkin lymphoma (cHL)

• Variability of HGAL staining between low-risk and intermediate-risk pediatric patients with cHL

• Variability of HGAL staining as assessed by tissue array in pediatric patients with intermediate-risk cHL

• Correlation of rapid or slow early response in the intermediate-risk group with HGAL protein expression

Interventions

microarray analysis GENETIC

protein expression analysis GENETIC

immunohistochemistry staining method OTHER

laboratory biomarker analysis OTHER

Eligibility Criteria

• Age: Up to 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Diagnosed with low-risk classical Hodgkin lymphoma

DISEASE CHARACTERISTICS: * Diagnosed with low-risk classical Hodgkin lymphoma (cHL) * Samples available from patients enrolled in the low-risk study COG-AHOD0431 and in the intermediate-risk cHL study COG-AHOD0031 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Children's Oncology Group: lead
• National Cancer Institute (NCI): collaborator

Biospecimen

Retention: SAMPLES WITH DNA

Tissue

MeSH Terms

Conditions

Lymphoma; Hodgkin Disease

Interventions

Microarray Analysis; Immunohistochemistry

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Microchip Analytical Procedures; Investigative Techniques; Histocytochemistry; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Histological Techniques; Immunologic Techniques

Study Officials

• Frank G. Keller, MD

  Emory Children's Center - Atlanta

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 2, 2011
• First Posted: June 3, 2011
• Study Start: May 1, 2011
• Primary Completion: May 1, 2016
• Study Completion: May 1, 2016
• Last Updated: May 17, 2016

Record last verified: 2016-05